AllergyTalk Disparities in Atopic Dermatitis Miniseries Episode 3: Improving Access to Treatment for AD in Minority and Underserved Populations

image

Price: FREE for members and non-members

This episode will describe best practices for addressing disparities in care for patients with atopic dermatitis and how to implement specific health equity strategies to improve access to atopic dermatitis care and increase patient adherence to treatment.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
This podcast is supported by an independent medical education grant from Pfizer..

Target Audience

Allergists and Immunologists

Learning Objectives

Understand how to address disparities in care for patients with atopic dermatitis and how to implement specific health equity strategies to improve access to atopic dermatitis care and increase patient adherence to treatment

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Attendance
Course opens: 
06/13/2022
Course expires: 
06/12/2025
Rating: 
0

All relevant financial relationships have been mitigated.

Andrew Alexis, MD, MPH | Grants: Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis, Dermavant |  Advisory Board: Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdof, Valeant, L'Oreal, BMS, Bausch Health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen, VisualDx, Eli Lilly, Swiss American | Speaker: Regeneron, SANOFI-Genzyme, Pfizer, BMS | Royalties: Springer, Wiley-Blackwell, Wolters Kluwer Health

Payel Gupta, MD, FACAAI | Advisor, Speaker: ALK

Marcella Aquino, MD, FACAAI, FAAAAI | No financial relationships to disclose.

Anil Nanda, MD, FACAAI, FAAAAI, FACP | No financial relationships to disclose.

 

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Attendance
Please login or create an account to take this course.